ADXS
Advaxis
Advaxis Inc. is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm). The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.The Lm-based platform on which the company’s products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient’s immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.
The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 28.74M; Volume: 676.09K; AvgVol 3m: 1.21M; Beta: 3.40;
Cost estimate:
P/E: –; EPS: -0.60; EPS growth quarter/prev quarter: 90.50%;
EPS growth this year: 94.40%; EPS growth past 5 years: 40.40%;
EPS ttm: -0.60;
P/S: 84.13; P/B: 0.77; P/Cashflow: 01.06; P/FCF: ;
Sales: 250.00K; Sales growth quarter/prev quarter: ; Sales growth past 5 years: 83.60%;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -66.40%; ROE – return on equity: -81.60%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.47%; Insider Transactions:0.00%;
Institutional Ownership: 18.40%; Institutional Transactions: 2.03%;
Data update: 07.10.2020.